NRC FORM 591M PART 1
(07-2012)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Spectrum Health Pennock 1009 West Green Street Hastings, Michigan 49058 REPORT NUMBER(S) 2016001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14015	21-18667-01	Nov. 29, 2016

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☒ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

_____ Non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Geoffrey M. Warren		11/29/16
BRANCH CHIEF	Aaron T. McCraw		12/21/16

NRC FORM 591M PART 3
(07-2012)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Spectrum Health Pennock 1009 West Green Street Hastings, Michigan 49058 REPORT NUMBER(S) 2016001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14015	21-18667-01	November 29, 2016

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87131	03.01 - 03.09

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02120	3	Eric Ward, M.D., RSO	(269) 945-1212

☑ Main Office Inspection Next Inspection Date: Nov. 2019

☐ Field Office Inspection _____

☐ Temporary Job Site Inspection _____

PROGRAM SCOPE

This was a routine, unannounced inspection. The licensee was a 50-bed hospital located in Hastings, Michigan, with authorization to use byproduct materials in Sections 35.100, 35.200, and 35.300. Licensed activities were conducted only at the location indicated on the license. The nuclear medicine department was staffed with two full-time nuclear medicine technologists, who typically administered 100 diagnostic doses monthly and one iodine-131 therapy dose annually. The diagnostic procedures were predominately technetium-99m cardiac, bone, and hepatobiliary imaging. The iodine-131 doses were received as capsules only. The department received unit doses as needed from a licensed nuclear pharmacy or prepared doses from bulk technetium obtained from the nuclear pharmacy. All waste was either held for decay-in-storage (DIS) or returned to the nuclear pharmacy.

Performance Observations: No diagnostic or therapeutic procedures were performed during the inspection. Licensee staff demonstrated morning hot lab checks, package receipt surveys and wipes, and daily and weekly contamination surveys, and described diagnostic and therapeutic administrations of licensed materials. The inspector noted no concerns with these activities. The inspector reviewed written directives for radiopharmaceutical therapies and identified no concerns. Interviews with licensee personnel indicated adequate knowledge of radiation safety concepts and procedures. Review of dosimetry records indicated no exposures of concern. The inspector performed independent and confirmatory radiation measurements which indicated results consistent with licensee survey records and postings.

No violations of NRC requirements were identified as a result of this inspection.